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Abstract: BACKGROUND Most glioblastoma recurrences occur near prior radiation treatment sites.
Future clinical success will require achieving and optimizing an ’abscopal effect’, whereby un-irradiated
neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radia-
tion combined with anti-PD-L1 demonstrated modest efficacy in phase II human glioblastoma clini-
cal trials, but the mechanism and relevance of the abscopal effect during this response remains un-
known. METHODS We modified an immune-competent, genetically-driven mouse glioma model (forced
PDGF expression + PTEN loss) where a portion of the tumor burden is irradiated (PDGF) and an-
other un-irradiated luciferase expressing tumor (PDGF+Luciferase) is used as a readout of the abscopal
effect following systemic anti-PD-L1 immunotherapy. We assessed relevance of tumor neoepitope dur-
ing the abscopal response by inducing expression of EGFRvIII (PDGF+EGFRvIII). Statistical tests
were two-sided. RESULTS Following radiation of one lesion, anti-PD-L1 immunotherapy enhanced
the abscopal response to the un-irradiated lesion. In PDGF-driven gliomas without tumor neoepitope
(PDGF+Luciferase, n=8), the abscopal response occurred via anti-PD-L1-driven, ERK-mediated, bone
marrow-derived macrophage phagocytosis of adjacent un-irradiated tumor cells, with modest survival
implications (median survival 41 days vs. radiation alone 37.5 days, P=.03). In PDGF-driven gliomas
with tumor neoepitope (PDGF+EGFRvIII, n=8), anti-PD-L1-enhanced abscopal response was associ-
ated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs.
radiation alone 28 days, P=.001). CONCLUSION Our results indicate that anti-PD-L1 immunotherapy
enhances a radiation induced abscopal response via canonical T-cell activation and direct macrophage
activation in glioblastoma.
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Background: Most glioblastoma recurrences occur near prior radiation treatment sites. Future clinical 
success will require achieving and optimizing an ‘abscopal effect’, whereby un-irradiated neoplastic 
cells outside treatment sites are recognized and attacked by the immune system. Radiation combined 
with anti-PD-L1 demonstrated modest efficacy in phase II human glioblastoma clinical trials, but the 
mechanism and relevance of the abscopal effect during this response remains unknown. 
Methods: We modified an immune-competent, genetically-driven mouse glioma model (forced PDGF 
expression + PTEN loss) where a portion of the tumor burden is irradiated (PDGF) and another un-
irradiated luciferase expressing tumor (PDGF+Luciferase) is used as a readout of the abscopal effect 
following systemic anti-PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the 
abscopal response by inducing expression of EGFRvIII (PDGF+EGFRvIII). Statistical tests were two-
sided. 
Results: Following radiation of one lesion, anti-PD-L1 immunotherapy enhanced the abscopal response 
to the un-irradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF+Luciferase, n=8), 
the abscopal response occurred via anti-PD-L1-driven, ERK-mediated, bone marrow-derived 
macrophage phagocytosis of adjacent un-irradiated tumor cells, with modest survival implications 
(median survival 41 days vs. radiation alone 37.5 days, P=.03). In PDGF-driven gliomas with tumor 
neoepitope (PDGF+EGFRvIII, n=8), anti-PD-L1-enhanced abscopal response was associated with 
macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs. radiation 
alone 28 days, P=.001).  
Conclusion: Our results indicate that anti-PD-L1 immunotherapy enhances a radiation induced abscopal 
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Key Points: 
1. Radiation synergizes with anti-PD-L1 immunotherapy in glioblastoma 
2. Tumor neoepitope may enhance response to radiation and anti-PD-L1 immunotherapy 
3. Anti-PD-L1 antibody directly activate macrophage phagocytic activity independent of T-cells  
 
Importance of the Study: 
A recent phase II clinical trial assessing the combination of radiation and anti-PD-L1 immunotherapy in 
glioblastoma showed a modest improvement in patient survival. The relevance of the abscopal response 
or impact of tumor neoepitope for susceptibility of glioblastoma to radiation and anti-PD-L1 
immunotherapy remains unclear. We developed a representative RCAS/Tv-a luciferase-based 
glioblastoma model that allows for real-time assessment of the abscopal response following radiation of 
adjacent non-luciferase expressing glioblastoma. Glioblastoma with tumor neoepitope such as EGFRvIII 
are more susceptible to the abscopal response with significant macrophage and T-cell infiltration. In 
other glioblastoma without neoepitope expression, anti-PD-L1 antibodies enhances a radiation induced 
abscopal response through direct activation of an anti-tumor and pro-inflammatory phenotype in 
macrophages. Our results indicate that radiation and anti-PD-L1 induced abscopal response in 













Glioblastoma is a highly aggressive intrinsic brain tumor that is diffusely infiltrative into the 
brain parenchyma.1 Most recurrences following standard treatment (surgery, chemotherapy, radiation) 
occur within 2 cm of the prior treatment location.2 Therefore, it is likely that any significant 
improvement in survival for glioblastoma patients will require assistance from the immune system to kill 
resistant/residual tumor cells outside prior treatment regions (abscopal response). During the abscopal 
response, radiation of specific tumors activates a systemic immune response to un-irradiated and distant 
tumor foci.3 In humans and mice, this effect is potentiated by immune checkpoint inhibitors, resulting in 
an anti-tumor immunologic response outside the radiation field, even within the central nervous system 
(CNS).4,5 
 
The clinical relevance of an abscopal effect on survival of patients with late stage non-small cell 
lung cancer (NSCLC) was previously assessed in a phase II prospective randomized clinical trial.6 
Results demonstrated that following a combination of radiation and anti-CTLA-4 immunotherapy, un-
irradiated distant lesions regressed. This regression was associated with T-cell activation, resulting in a 
significant improvement in progression free survival (PFS, median = 7.1 vs. 3 months, P<.001) and 
overall survival (OS, median 20.4 vs. 3.5 months, P<.001).6 A phase II prospective clinical trial 
combining radiotherapy with anti-PD-L1 immunotherapy (MEDI4736, Durvalumab) in newly diagnosed 
unmethylated glioblastomas demonstrated some efficacy, with median OS of 15.1 months versus a 
historical median OS of 12.7 months for new unmethylated glioblastoma.7 Although a phase III clinical 
trial is necessary to confirm these findings, it suggests that the combination of radiation and anti-PD-L1 




similar to NSCLC, the abscopal response contributes to this effect on survival. It is also unclear which 
tumor-specific factors, such as neoepitopes or peripheral immunosuppressive mechanisms, may 
influence susceptibility to this treatment combination.  Further, it remains uncertain what strategies 
could optimize the abscopal phenomenon for glioblastoma following radiation and anti-PD-L1 therapy. 
 
In the current study, we leverage the RCAS/Tva mouse model system to study factors 
influencing susceptibility to the abscopal response in the setting of standard targeted radiation combined 
with anti-PD-L1 immunotherapy. 
 
Materials and methods 
A detailed description of the Methods can be found in the Supplementary Methods (available 
online). All animal experiments were done in accordance with guidelines from the Institutional Animal 
Care and Use Committee, Fred Hutchinson Cancer Research Center (IAUCUC Protocol #50842).  
 
Mouse models of glioblastoma 
The RCAS/Tva model system was used to generate mouse glioblastoma.8,9 The 1) Tg(NTva); 
Cdkn2a (Ink4a-Arf)-/-; Ptenflox/flox (referred to as NTva), Tg(NTva); Cdkn2a (Ink4a-Arf)-/-; Ptenfloxlflox; 
LSL Luciferase and EGFRvIII. 2) Tg(NTva); Cdkn2awt; Ptenflox/flox; CX3CR1+/GFP; CCR2+/RFP mice10 
were used as genetic backgrounds for RCAS mediated glioblastoma formation. Details of the full 
EGFRvIII cDNA which also encodes the unique EGFRvIII splice junction peptide or neoepitope 
(Peptide sequence-LEEKKGNYVVTDH) and mice strains used for conditional over-expression were 
previously described11,12 and summarized in supplemental methods online. For bilateral tumor models, 




RCAS-shPten into the contralateral hemisphere, two genetically similar tumors develop, with one tumor 
lacking luciferase expression (PDGFB/shPten; radiated glioblastoma) and the other tumor demonstrating 
luciferase or EGFRvIII expression (un-irradiated glioblastoma).  
 
Bilateral tumor formation in vivo 
Bilateral tumors were generated in 4-6-week-old male and female adult mice. DF1 cell delivery 
was performed with a 30-gauge needle attached to a Hamilton syringe and stereotactic fixation device 
(Stoelting, Wood Dale, IL). Cells were injected into the frontal cortex of each hemisphere, 3mm lateral 
to bregma and a depth of 1mm. Mice were monitored carefully for signs of disease and treatment began 
when the tumor was visible by bioluminescence or magnetic resonance imaging (MRI). 
 
Drug treatments in vivo 
Adult mice were sedated with isoflurane during radiation. 10Gy was delivered to the right 
hemisphere (non-luciferase tumor) while the left hemisphere (Luciferase or EGFRvIII expressing tumor) 
and rest of body was shielded to prevent radiation on non-target tissue. Restricted radiation was 
confirmed by phosphorylated histone 2AX (pH2AX) expression in the non-radiated hemisphere two 
hours post treatment. Endotoxin low (≤0.001 EU/µg; ≤ 1 EU/mg) and functional grade rat anti-mouse 
IgG2bκ (isotype control), anti-PD-L1 and anti-PD1 (10µg/g mouse body weight) were administered 
starting on the day of radiation (post tumor initiation day 15) and then daily until endpoint. 
Bioluminescence signals were obtained for each treatment group every 2-3 days following treatment. 
The last bioluminescence signal represents the last time point measured prior to reaching end-point (see 
Kaplan-Meier curve for end-points). Animals were sacrificed upon development of neurological 





Bioluminescence and MRI  
Bioluminescence imaging was obtained on the Xenogen IVIS 100 system. Mice with tumors 
expressing luciferase were anesthetized with isofluorane before intraperitoneal injection with 75mg/kg 
body weight D-luciferin (Caliper Life Sciences Part Number #119222). Ten minutes after injection, 
images were acquired for 3-5 mins. Total flux (photons seconds-1) was obtained from each mouse. An 
MRI scan (Bruker 1T scanner) was obtained immediately after or just prior to bioluminescence to 
delineate tumor and inflammation. Mice were imaged on this combination protocol the first day of 
treatment and 3, 5, 10, 14 and 21 days after treatment. Volume of interest were manually contoured 




Mouse brains were fixed in formalin and embedded in paraffin, then sectioned at 5µm and 
stained by routine hematoxylin and eosin (H&E), as well as immunohistochemistry (IHC). Automated 
Immunohistochemistry was performed on the Discovery XT, (Ventana Medical Systems Inc.) according 
to the manufacturer’s standard protocol.  
 
In vitro fluorescent labeled bacteria phagocytosis  
Following 8 hours of serum starvation, mouse macrophages were treated with specific antibodies 
for 24 hours. The effect of anti-PD-L1 antibodies on macrophage phagocytosis was assessed using the 





Selective ERK1/2 Pathway inhibition 
The selective ERK1/2 inhibitor PD98059 was purchased from Cell Signaling technology 
(#9909). For the in vitro studies, macrophages were serum starved for 8 hours and pre-incubated in 
specified concentrations of PD98059 1 hour prior to addition of anti-PD-L1 antibodies (20µg/ml). For 
western blot (ERK phosphorylation), cell lysates were obtained at 30 minutes and 3 hours following 
treatment with anti-PD-L1 antibodies. Mouse (Anti-PD-L1, BioXcell), Human (Avelumab, Merck and 
Atezolizumab, Genentech).  
 
Differentiation of monocytes into macrophages in vitro 
At least three biological replicates were used in each mouse macrophage experiment, while 
donor human peripheral monocyte derived macrophages were evaluated per antibody tested. To obtain 
enough starting mouse monocytes for macrophage differentiation, one mouse bone marrow derived 
macrophage biological replicate was derived from pooling bone marrow from the hind legs of four 
separate mice. Mouse bone marrow derived monocytes were harvested from NTva; Ink4a/arf-/-; 
Ptenflox/flox mice and differentiated into macrophages with 50µg/mL of macrophage colony stimulating 
factor (M-CSF) in RPMI medium with 10% fetal bovine serum (FBS) for 6 days. Mouse macrophages 
were re-plated at 5x105 cells per well (6-well plate) and allowed to rest overnight prior to treatments. 
Flow cytometry for CD11b, F4/80, PD-L1 and PD-1 were performed to verify mouse bone marrow 
derived macrophages generated in vitro. 
 
Antibody depletion of T-cells 
On post-tumor initiation day 10, 15, 19, 22 and 30 tumor bearing mice were treated with 0.4mg 




BE0090), rat anti-CD4 (GK1.5 clone, BioXCell BE0003-1) and rat anti-CD8 (2.43 clone, BioXCell 
BE0061). Spleens (n=2) were harvested from each treatment group on post-tumor initiation day 22 and 
evaluated by flow cytometry for T-cell depletion using the following antibodies; CD8-PE 
(Biolegend 100708) and CD4-APC (Biolegend 100515). 
 
Nanostring gene expression analysis  
Conditions for Nanostring gene expression profiling were untreated and anti-PD-L1 (20µg/ml). 
Conditions for Real time PCR verification were isotype control (negative control), lipopolysaccharide 
(LPS; positive control, Sigma L3024), anti-PD-L1 (20µg/ml) and soluble rhPD-1-fc (20µg/ml). 
Following specified treatment for 200 minutes, media was aspirated, cells were rinsed in sterile PBS and 
lysed in RTL (Qiagen 1015750) + 1% BME (Biorad 161-0710) at 3,500 cells/µL per Nanostring 
recommendations. (PCR samples were lysed in 350µL). The mouse myeloid innate immunity panel 
(XT-PGX-MMV2-Myeloid, Nanostring 11500181) was used to assess the expression of immune related 
genes following treatment per Nanostring protocol. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad prism 7 (GraphPad Software, San Diego, 
CA). Data were expressed as mean (SEM). Two-sided Mann-Whitney U tests were used to compare 
groups. In Figure 3A-D, the Holm-Bonferroni multiple comparison post hoc test was performed to 
compare differences between groups. For survival studies, the Kaplan-Meier analysis was performed 






Effects of anti-PD-L1 and anti-PD-1 immunotherapy on survival of bilateral PDGF-driven 
glioblastoma bearing mice following unilateral radiation therapy 
To visualize and optimize the abscopal response for glioblastoma in vivo, we generated two 
genetically distinct PDGF-driven glioblastomas within the brain. In one hemisphere, we induced a 
PDGF-shPten-driven glioblastoma, while in the other hemisphere we generated a PDGF-driven 
glioblastoma with Luciferase expression (Figure 1A; Ntva Ink4a/Arf-/- Ptenflox/flox mice with Lox-Stop-
Lox Luciferase) via deletion of the Lox-STOP-Lox sequence through injection of RCAS-Cre only in one 
side (Figure 1A, top). To evaluate the influence of specific tumor neoepitope expression during an 
abscopal response, we induced unilateral expression of EGFRvIII which contains the unique fusion 
junction peptide, LEEKKGNYVVTDH (Figure 1A; Ntva Ink4a/Arf-/- Ptenflox/flox mice with Lox-Stop-
Lox EGFRvIII) via deletion of the Lox-STOP-Lox sequence through injection of RCAS-Cre only in one 
side (Figure 1A, bottom). In the PDGF-Luciferase (PDGF+Luc) mice, restriction of luciferase 
expression to one hemisphere (the non-radiated side) allowed the unilateral bioluminescence readout of 
tumor cell viability following radiation of the other hemisphere. Radiation-induced damage was 
restricted to the radiated hemisphere as determined by phospho-histone 2A.X immunostaining two hours 
post radiation treatment (Supplemental Figure 1A). Post radiation tumor growth was assessed in vivo by 
two methods: 1) MRI to visualize bilateral tumor growth (Figure 1B; left) and 2) bioluminescence as a 
readout of tumor cell viability on the non-radiated hemisphere (Figure 1B; right. Correlation between 
MRI and bioluminescence, Figure 1C; R2 =0.9649). 
 
We then assessed how checkpoint inhibition could functionally enhance targeted immune 
response to un-irradiated tumor in vivo by determining the relative effects of systemic anti-PD-L1 and 




with unilateral radiation. Administration of anti-PD-L1 immunotherapy in conjunction with unilateral 
radiation resulted in a modest improvement in survival in PDGF+Luc glioblastoma (n=7-8/group, 
median survival = 40.5 days vs. radiation alone 37.5 days, Log-rank P=.03, Figure 1D). In 
PDGF+EGFRvIII glioblastoma, there was increased improvement in survival following anti-PD-L1 
immunotherapy and unilateral radiation (n=8/group, median survival = 36 days vs. radiation alone 28 
days, Log-rank P=.001, Figure 1E). In a one-sided brain tumor model, 10Gy unilateral radiation to non-
tumor brain had no effect on survival (Supplemental Figure 1B-C). This indicated that combination 
therapy (radiation and systemic anti-PD-L1) was superior to monotherapy (systemic anti-PD-L1 alone) 
in the RCAS/TV-a glioblastoma mouse model. Of note, this response occurs in the absence of 
significant PD-L1 expression within the PDGF+Luc or PDGF+EGFRvIII micro-environment 
(Supplemental Figure 2A-B for Multiplexed Immunohistochemistry). 
 
Comparison of bioluminescence activity with brain MRI for in vivo measurement of tumor cell 
viability following combined glioblastoma therapy 
To determine if the enhanced survival benefit from combined radiation and anti-PD-L1 
immunotherapy is associated with reduction of tumor cell viability on the contralateral non-radiated 
side, we compared changes in routine MRI signal, representing tumor volume and inflammation, to 
luciferase activity, representing tumor viability in the PDGF+Luc model. In IgG control treated animals, 
an increase in un-irradiated tumor growth corresponded with increased MRI signal (n=8/8, Figure 2B).  
As a positive control, whole brain radiation with 10Gy caused a decrease in both MRI signal and 
luciferase activity (n=4/4, Figure 2B). Monotherapy with daily systemic anti-PD-L1 antibodies (10µg/g) 
had no impact on tumor progression based on MRI imaging or luciferase activity (n=0/4, Figure 2B). 




subset of these tumors concurrently showed a small but not significant decrease in viable tumor cell 
numbers as measured by reduced luciferase activity, indicating a potential abscopal effect for unilateral 
radiation alone occurring in only a few treated animals (n=2/4, Figure 2B).  Conversely, concurrent daily 
systemic anti-PD-L1 immunotherapy enhanced this abscopal effect of 10Gy radiation on the un-
irradiated, luciferase-containing tumor.  This combined therapy resulted in a decrease of tumor cell 
viability in 8/8 mice (100%) and an increase in MRI signal in 5/8 mice (62.5%, Figure 2B; tumor cell 
viability or luciferase activity for all groups shown in Figure 2C). The discordance between loss of 
viable tumor cell and increased tumor size may represent treatment-induced inflammation 
(pseudoprogression) and/or edema falsely mimicking tumor progression on MRI. These results 
suggested that, following radiation and anti-PD-L1 immunotherapy, regression of un-irradiated lesions 
may contribute to improved survival in the bilateral brain tumor model. 
 
Effect of anti-PD-L1 immunotherapy on radiation therapy-mediated recruitment of macrophages 
and T-cells into brain tumors 
To investigate the relevance of tumor neoepitope expression during the abscopal response, we 
histologically quantified macrophage (Iba1+) and T-cell (CD3+) infiltration into tumors on both 
irradiated and un-irradiated sides of both glioma models (PDGF+Luc and PDGF+EGFRvIII) after 
treatment with radiation and anti-PD-L1 immunotherapy on post-treatment day 10. Relative to IgG 
isotype control (n=5), 10Gy radiation and daily anti-PD-L1 immunotherapy (n=5) induced a significant 
macrophage (P<.0001) and T-cell (P<.0001) infiltration into both un-irradiated and radiated sides of 
PDGF+EGFRvIII gliomas (Figure 3A-D, 3F). In PDGF-Luc gliomas (n=5), relative to IgG isotype 
control (n=5), there was an absence of T-cell infiltration (P>.05).  However, a macrophage-predominant 




3E). These results indicated that following radiation and anti-PD-L1 immunotherapy, the slightly higher 
survival advantage noted in the neoepitope expressing PDGF+EGFRvIII glioma bearing mice (relative 
to the PDGF+Luc glioma mice) may be due to an inherent ability to recruit T-cells into un-irradiated and 
irradiated tumors. 
  
In PDGF+Luc gliomas (lacking tumor neoepitope), systemic depletion of circulating CD4+ and 
CD8+ T-cells did not affect the survival benefit associated with radiation combined with anti-PD-L1 
immunotherapy (Figure 4 A-C). Therefore, to investigate the impact of macrophage recruitment on 
glioma growth independent of T-cell activation, we sought the source of tumor-infiltrating macrophages 
following radiation and anti-PD-L1 immunotherapy.  We generated bilateral PDGF-Pten-/- glioblastoma 
(lacking tumor neoepitope) in the NTva; Cdkn2awt; Ptenflox/flox; CX3CR1+/GFP; CCR2+/RFP mouse model. 
Here, CX3CR1+/GFP and CCR2+/RFP delineate microglia (GFP+) and peripheral monocytes (RFP+), 
respectively, and double positive CX3CR1+/GFP/CCR2+/RFP delineates peripherally derived tumor-
associated macrophages (GFP+/RFP+).13 Relative to radiation alone (n=6), the addition of daily anti-PD-
L1 immunotherapy to unilateral 10Gy radiation (n=6) significantly increased the numbers of double 
positive CX3CR1+/GFP/CCR2+/RFP circulating monocyte-derived macrophages in both un-irradiated 
(median increase 40%, P<.01) and radiated bilateral tumors on post-treatment day 5  (median increase 
30%, P<.01), (Figure 4D and 4E; Flow cytometry gating strategy in Supplemental Figure 3A).  It also 
demonstrated a loss of microglia (shown as a percentage of viable cells) within the radiated tumor, 
consistent with a known consequence of direct radiation on the tumor micro-environment.14 Further 
investigation of this macrophage response showed that, similar to human glioblastoma,15 RCAS/Tv-a 
glioblastoma-bearing mice demonstrated elevated levels of  immunosuppressive PD-L1+/Ly6C+ 




PDGF+EGFRvIII healthy and tumor mice) (P<.01), (Supplemental Figure 3B; Flow cytometry gating 
strategy in Supplemental Figure 3C). Following a combination of radiation and anti-PD-L1 
immunotherapy, flow cytometry of tumors from PDGF-Pten-/- glioblastoma in the 
CX3CR1+/GFP/CCR2+/RFP model demonstrated that, relative to radiation alone (n=6), combining radiation 
with daily anti-PD-L1 immunotherapy (n=6) increased the fraction of Ly6C+ immune cells (shown as 
percentage of all viable cells) within both irradiated and un-irradiated tumors on post-treatment day 5 
(P<.01), (Supplemental Figure 3D; Flow cytometry gating strategy in Supplemental Figure 3F). Further, 
increased levels of the PD-L1+/Ly6C+ sub-population infiltrated the non-radiated tumor (P<.05), 
(Supplemental Figure 3E; Flow cytometry gating strategy in Supplemental Figure 3F). These data 
suggested that the combination of radiation and anti-PD-L1 immunotherapy enhanced recruitment of 
bone marrow derived immunosuppressive PD-L1+ monocytes into adjacent un-irradiated glioblastoma 
as tumor-associated macrophages. 
 
Effect of anti-PD-L1 antibodies on monocyte-derived macrophage activation in vitro 
Previous research has shown that anti-PD-1 antibody direct activation of PD-1+ macrophages, 
independent of T-cell activation, results in a pro-inflammatory, anti-tumor phenotype in tumor-
associated macrophages.16 Therefore, we investigated whether anti-PD-L1 antibodies could also directly 
induce an anti-tumor phenotype in bone marrow derived PD-L1+ macrophages ex vivo. Incubation of 
bone marrow derived M-CSF differentiated PD-L1+/CD11b+/F4/80+ macrophages (Supplemental Figure 
4A; flow cytometry gating strategy in Supplemental Figure 4B) with anti-PD-L1 antibodies induced a 
shift in gene expression in mouse macrophages in vitro (Supplemental Table S1). Upregulation of 95 
myeloid-related genes, and downregulation of 44 genes, was induced with anti-PD-L1 treatment 




production (Figure 5A and 5B).  There was evidence of signaling associated with both activation and 
inhibition of macrophage function (Supplemental Table S2) indicating that subsequent macrophage 
phenotype is dependent on the balance between pro-inflammatory and pro-tumor gene expression or 
signaling pathways. Targeted myeloid-related gene expression was validated by real-time quantitative 
PCR (RT-qPCR) using an isotype negative control (IgG2b), lipopolysaccharide (LPS) as positive 
control, Fc conjugated soluble PD-1 (sPD-1-Fc, IgG1 isotype) and anti-PD-L1 antibody (IgG2b isotype). 
Relative to isotype control, anti-PD-L1 induced significant increases in pro-inflammatory gene 
expression in macrophages (Olr1, Cxcl3, and Ccl3, P<.01), (Supplemental Figure 4C and Supplemental 
Table S3 and S4).  sPD-1 was equally effective at inducing pro-inflammatory gene expression changes 
relative to anti-PD-L1 antibody, illustrating the on-target effects of anti-PD-L1 (P<.01), (Supplemental 
Figure 4C).  
 
Effect of anti-PD-L1 antibodies on macrophage phagocytic activity via extracellular signal-related 
kinase (ERK) pathway activation 
Gene ontology on the Nanostring gene expression data was indicative of both activation and 
inhibition of ERK pathway following incubation of PD-L1+/PD-1- mouse macrophages with an anti-PD-
L1 antibody, with more significance in ERK activation signaling pathways (Figure 5A). To further 
explore this, we expanded the treatment regimen of mouse macrophages in vitro to include two clinical 
grade human anti-PD-L1 antibodies: Avelumab and Atezolizumab. All mouse and human anti-PD-L1 
antibodies induced ERK phosphorylation in their respective macrophages in vitro (Figures 5C, 5D, 5E 
and 5F). This effect was not observed when PD-L1 treated macrophages were exposed to the selective 
ERK inhibitor PD98059 (Figures 5C, 5D, 5E and 5F). Functionally, anti-PD-L1 antibodies also 




L1-driven phagocytic effect was reversed by pre-treatment of the macrophages with the selective ERK 
inhibitor PD98059 (P<.0001) (Figure 6A). In vivo, following radiation and anti-PD-L1, there was also 
increased phagocytosis of tumor cells based on immunohistochemical colocalization of Olig2+ tumor 
cells within Iba1+ macrophages in both irradiated and un-irradiated low baseline intra-tumoral 
PDGF+Luc glioblastoma (P<.01), (Figure 6B and 6C). Anti-PD-L1 treatment alone did not increase 
phagocytosis of tumor cells in-vivo (Data not shown). This indicated that following a radiation-induced 
recruitment of the immunosuppressive PD-L1+ monocytes to brain tumors, anti-PD-L1 antibodies 
directly induced a pro-inflammatory and anti-tumor phenotype in PD-L1+ tumor-infiltrating 




The specific mechanism mediating the abscopal phenomenon remains an enigma. Based on a 
metanalysis, the relative contribution of antigen-presenting cells (APCs) such as macrophages, dendritic 
cells or T-cells to the abscopal response varies depending on radiation schedule, dosage, animal model 
or immune checkpoint inhibitor used.17 Prior to T-cell activation during the abscopal response, 
radiation-induced tumor death results in release of neo-antigens or neo-epitopes which are engulfed by 
APCs.18 APCs then circulate to lymph nodes where neo-antigen presentation results in activation and 
education of naïve T-cells. Activated and tumor-specific T-cells enter the circulation and selectively 
target tumor cells, resulting in regression of un-irradiated tumors.  
 
Even though the abscopal response is well known in other cancer types, the complete mechanism 




glioblastomas with neoepitopes such as EGFRvIII tumors may be more susceptible to an immunological 
mediated abscopal response, although the functional significance of T-cell infiltration or neo-epitope 
type for survival is currently being investigated. A majority of glioblastoma, however, lack neo-epitope 
expression.19 Therefore, uncovering strategies that enhance the immunologic response to glioblastoma in 
the absence of neo-epitope associated T-cell recruitment may improve survival. Direct activation of 
macrophages has been associated with the abscopal response in the absence of T-cell infiltration.20-22  
Given the critical role of macrophages demonstrated in the response to immunotherapy in our model, a 
better understanding of mechanisms that could enhance the macrophage-dependent abscopal effect is 
warranted. One possibility is the release of inflammatory cytokines or death associated molecular 
patterns (DAMPs) from dying tumor cells.18,21,22 Following radiation induced recruitment to the brain, 
infiltrating macrophages are polarized by anti-PD-L1 antibodies into anti-tumor states resulting in 
eradication of previously viable tumor cells just outside of the irradiated area (the bystander effect). A 
second possibility is that macrophages are ‘educated’ by tumor antigens released following irradiation 
resulting in a tumor specific response. The mechanism behind this macrophage ‘education’, however, 
remains unknown and warrants further investigation.  
 
Although blockade of PD-1 and PD-L1 are often thought of as equivalent, the effect of anti-PD-1 
in our mouse model is not similar to anti-PD-L1. One reason for this phenotypic distinction is that anti-
PD-L1 seems to directly activate PD-L1+ macrophages to increase production of cytokines and enhance 
phagocytosis in an ERK signaling-dependent manner.  Since glioblastomas are enriched with 
macrophages (20-30% of tumor mass),23-26 these immune cells may serve as better agents for achieving 
an immune-induced therapeutic effect. In some late stage cancer types, anti-PD-1 also activates 




these macrophages. In glioblastoma there is little PD-1 expression within the tumor and on circulating 
monocytes of tumor-bearing mice. By contrast, PD-L1 is expressed at higher levels on circulating 
monocytes of tumor bearing mice and human glioblastoma patients.15 A recent report showed that anti-
PD-L1 antibodies  directly activate bone marrow derived macrophages in-vitro,27 indicating that similar 
to anti-PD-1, anti-PD-L1 activated macrophages could also mediate an anti-tumor response 
independently of T-cell activation. Given that macrophages comprise the largest immune cell population 
in glioblastoma and PD-L1+ circulating monocyte-derived macrophages are the cells that respond 
primarily to radiation therapy,28 it is not surprising that after radiation therapy, mouse glioblastoma 
respond better to anti-PD-L1 therapy which specifically target infiltrating PD-L1+ macrophages, than to 
anti-PD-1 immunotherapy.  
 
In our model, we also found that anti-PD-L1 monotherapy treated mice had poorer survival 
relative to IgG control treated mice. Although it remains unclear why this occurred, it indicates that 
without radiation therapy, anti-PD-L1 therapy may have a unique profile of targets and consequently a 
different outcome in tumor bearing mice not receiving radiation therapy. Also, because patients with 
PD-L1-negative tumors also respond to anti-PD-L1 therapy,29 our results indicate that levels of PD-L1+ 
monocytes in circulation, not tumor PD-L1 expression, may be a better prognostic indicator of response 
to anti-PD-L1 therapy following radiation for glioblastoma patients. To the degree that the mouse model 
reflects human biology, our results also suggest that patients with glioblastoma that fail anti-PD-1 or 
anti-PD-L1 monotherapy could still respond to anti-PD-L1 combined with high-dose radiation of viable 





Our study has several limitations. Since the gene expression profiling is based on macrophages 
cultured in-vitro, it may not represent the macrophage phenotype in-vivo therefore, we plan to perform 
gene expression analysis from tumor cells and macrophages post-treatment in-vivo. Also, given the 
limited specificity of CCR2 and CX3CR1 as immune cell markers, we also plan to perform lineage 
studies using fluorescence tagged bone marrow precursors to selectively track monocytes and 
macrophages following radiation and anti-PD-L1 therapy. The scope of genetic alterations assessed is 
also a limitation, therefore, we plan to assess the impact of other clinically significant mutations such as 
isocitrate dehydrogenase 1 (IDH1) mutation.    
 
In summary, experimentally-tractable models with representative histology in immune-
competent mouse backgrounds are needed to optimize the abscopal effect for brain tumors. Such 
experimental systems also need to be robust at detecting, monitoring, and studying the abscopal effect in 
live animals following administration of diverse immunotherapeutic agents irrespective of route of 
administration. Using the RCAS/Tv-a system, we find that anti-PD-L1 immunotherapy enhances a 
radiation therapy induced abscopal response. In tumors such as glioblastoma, where recurrence is driven 
by infiltrated tumor cells in the periphery of the radiation treatment regions, combinatorial strategies that 
induce an abscopal or bystander effect in patients will be critical for establishing local disease control 
and improving overall survival. 
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Figure 1. Combined unilateral radiation and systemic anti-PD-L1 immunotherapy increases 
survival in a bilateral glioblastoma model. (A) Strategy for inducing mouse bilateral glioblastoma 
within the brain using the RCAS/Tva mouse model for immune micro-environment profiling and Cre-
recombination strategy used to generate unilateral luciferase expressing PDGF+Luc (top) and 
PDGF+EGFRvIII (bottom) tumors (Tg(NES-TVA);Cdkn2a (Ink4a-Arf)-/-;Ptenfl/fl; LSL Luciferase and 
EGFRvIII mice). (B) Representative magnetic resonance imaging (MRI, left panel) of a bilateral 
glioblastoma mouse model. Right panel is bioluminescence signal from mouse in left panel, showing 
unilateral luciferase activity from the left-sided PDGF-Pten-/- tumor only. Red arrows delineate tumors 
on each side of brain. Scale bar=1mm. (C) Correlation between tumor viability (luciferase activity) and 
MRI T2-weighted signal in IgG-treated animals bearing bilateral glioblastoma (n=8 mice, R2=0.9649). 
Two to three representative MRI scans highlighting interval growth in one untreated animal with arrows 
showing direction of growth between scans. Red circles are measurements from time point 1 (Post-
tumor initiation day 17), blue circles are measurements from time point 2 (Post-tumor initiation day 20) 
and green circles are measurements from time point 3 (Post-tumor initiation day 23). Y-axis in 
logarithmic scale (Photons second-1). X-axis in linear scale (mm3). (D-E) Kaplan-Meier survival curves 
showing that anti-PD-L1 immunotherapy enhances unilateral radiation-induced survival in bilateral 
PDGF+Luc (D) and PDGF+EGFRvIII (E) glioblastoma (n=6-8 mice per treatment group). Red arrow 
indicates unilateral 10Gy irradiation. Blue arrow indicates daily anti-PD-L1 or anti-PD-1 treatments. 
Treatments began on post-tumor initiation day 15. Log-rank Mantel–Cox test for radiation alone versus 





Figure 2. Abscopal effect of combined localized radiation and systemic anti-PD-L1 
immunotherapy. (A) Depiction of experimental strategy of bilateral mouse glioblastoma to measure 
abscopal effect in Tg(NTva);Ink4a-Arf-/-;Pten-/-; LSL Luciferase mice with left-sided PDGF-Pten-/- 
Luciferase tumor and right-sided PDGF-shPten tumor. The right hemisphere contains a non-luciferase 
tumor and is radiated. The left side contains neoplastic cells harboring luciferase expression and is not 
radiated. Tumor viability (Photons seconds-1) and MRI tumor volume (mm3) are obtained from the left-
sided, non-radiated tumor only. (B) Association between tumor viability (Photons seconds-1) and MRI 
tumor volume (mm3) for all treatment groups. The growth pattern of each individual animal is shown as 
black lines and the linear regression summation of all the animals in the treatment group are depicted as 
colored wide arrows. Mice receiving combination imaging included IgG control (n=8, red), whole brain 
radiation (n=4, purple), non-luciferase tumor radiation alone (n=4, magenta), anti-PD-L1 alone (n=4, 
blue) and non-luciferase tumor radiation with anti-PD-L1 (n=8, green). Tumor viability (luciferase 
activity in photons second-1) and MRI T2 signal volume (mm3) is shown relative to pre-treatment 
starting point that was normalized to 100% for all mice. (C) Response of un-irradiated tumor to 
treatment is categorized as transient tumor regression (TTR) or sustained tumor regression (STR). TTR 
represents any decrease in un-irradiated tumor viability (luciferase activity) that is followed by un-
irradiated tumor re-growth. STR represents any decrease in un-irradiated tumor viability that is not 
followed by un-irradiated tumor re-growth prior to reaching endpoint. Relative to IgG treated animals 
(red), whole brain radiation (10Gy) or radiation positive control induces TTR in 7 of 7 mice with STR in 
0 of 7 mice. Anti-PD-L1 antibody alone does not induce TTR or STR in any mice (0 of 7 mice). 
Unilateral radiation of non-luciferase expressing tumor induces TTR in 2 of 7 mice with STR in 0 of 7 
mice. Unilateral radiation of non-luciferase tumor and anti-PD-L1 antibodies induces TTR in 6 of 8 




viability, with growth showing increase and treatment response showing decrease on a log10 scale. IgG 
isotype control is the same for all treatment groups and shown in red, relative to experimental group 
shown in blue.  
 
Figure 3. Localized radiation and systemic anti-PD-L1 immunotherapy promotes intra-tumoral 
macrophage and T-cell infiltration. (A-B). Quantification of Iba1+ macrophage influx into un-
irradiated or abscopal side (A) and radiated side (B) based on immunohistochemistry on PDGF+Luc 
(red) and PDGF+EGFRvIII (blue) mouse gliomas on post-treatment day 10, n=5 mice per group. (C-D). 
Quantification of CD3+ T-cells macrophage influx into un-irradiated or abscopal side (C) and radiated 
side (D) based on immunohistochemistry on PDGF+Luc (red) and PDGF+EGFRvIII (blue) mouse 
gliomas following treatment, n=5 mice per group. (E-F) Representative immunohistochemistry for 
macrophages (Iba1) in PDGF+Luc gliomas (E) and T-cells (CD3) in PDGF+EGFRvIII gliomas (F) 
following treatment (Abscopal side). 3-5 high powered fields were counted per tumor sample from 5 
different tumors on post-treatment day 10. Scale bar=50µm. P-values derived from the non-parametric 
Mann-Whitney U test, two-sided. Holm-Bonferroni multiple comparison post hoc test for A-D. Error 
bars=SEM. P <.05- *, P <.01- **, P <.001-***, P<.0001-****, NS=not significant.  
 
Figure 4. T-cell depletion does not affect abscopal effect in PDGF+Luc glioblastoma  
(A-B) Bioluminescence (A) and survival data (B) from Tg(NTva);Ink4a-Arf-/-;Pten-/-; LSL Luciferase 
mice with left-sided PDGF-Pten-/- Luciferase tumor and right-sided PDGF-shPten tumor treated with 
anti-mouse IgG2b isotype control (n=7), anti-CD8 (n=8) and anti-CD4 (n=8) depleting antibodies at 10, 
15, 19, 22 and 30 days post-tumor initiation (black arrows in B). Unilateral 10Gy radiation was then 




measured within 10 days post-treatment initiation, abscopal response seen in 7/7 IgG treated mice, 8/8 
CD8+ T-cell depleted mice and 8/8 CD4+ T-cell depleted mice.  Survival curves following T-cell 
depletion in radiation and anti-PD-L1 treated mice showing no impact of T-cell depletion on survival 
(B). Log-rank Mantel–Cox test for radiation alone versus radiation with anti-PD-L1. P <.01- **, NS=not 
significant. (C) To verify T-cell depletion, flow cytometry was performed on spleens harvested from 
combination therapy treated mice (n=2 per group) on post-tumor initiation day 22 after 2 doses of 
depleting antibodies demonstrating >90% depletion. (D and E) On post-treatment day 5, relative to 
radiation alone (n=6, red), combination therapy with anti-PD-L1 immunotherapy (n=6, blue) is 
associated with increased infiltration of bone marrow derived macrophages (CX3CR1+/GFP/CCR2+/RFP) 
into the non-radiated/abscopal side as shown in D, and radiated side as shown in E, of bilateral RCAS-
PDGF-driven glioblastoma in Ntva; Cdkn2awt; Ptenflox/flox; CX3CR1+/GFP; CCR2+/RFP mice. Red circles 
are unilateral radiation treated mice, blue squares are unilateral radiation and anti-PDL1 treated mice. 
P-values derived from the non-parametric Mann-Whitney U test, two-sided. Error bars=SEM. P <.01- 
**, NS=not significant.  
 
Figure 5. Anti-PD-L1 antibodies directly activate bone marrow derived macrophages.  
(A and B) Gene ontology analysis of differentially expressed genes following incubation of anti-PD-L1 
antibodies with macrophages in vitro. Cell signaling pathways are shown in A and cell cycle/cytokine 
activation shown in B. We noted both activating and inhibitory signaling following anti-PD-L1 
treatment of macrophages in-vitro (Red – upregulation; Blue – downregulation). Gene expression is 
based on average fold-change from mouse bone marrow derived macrophages from three different mice 
pools. (C-F) Anti-PD-L1 antibodies induces ERK phosphorylation (p44/42) in mouse bone marrow 




quantified in E and F. Lysates were collected at 30 minutes and 3 hours post-treatment with anti-PD-L1 
antibodies. Two clinical grade human monoclonal antibodies (mAb) were evaluated including 
Avelumab (Bavencio, Merck, Kenilworth, New Jersey) and Atezolizumab (Tecentriq, Genentech, San 
Francisco, California). Selective ERK inhibition with PD98059 (Cell Signaling) is shown in a dose 
dependent manner. Matched isotype antibody was used as a negative control. Total ERK is the loading 
control. Results were independently replicated in different mouse bone marrow derived macrophages 
derived from three different mice pools and two different healthy human peripheral blood mononuclear 
cells donors.  
 
Figure 6. Anti-PD-L1 enhances macrophage phagocytosis in PDGF+Luc gliomas  
(A) Anti-PD-L1 antibodies promote phagocytosis of FITC-labelled E.coli particles in vitro via ERK 
signaling in PD-L1+/PD-1- murine macrophages. Phagocytosis of the particles was measured by a 
Vybrant phagocytosis assay kit. This anti-PD-L1 effect on macrophages is inhibited by PD98059, an 
ERK inhibitor (20µM). Three biological replicates each, with three technical replicates are shown. 
Orange are IgG controls, pink are FcγR (CD16/32) receptor block, blue are anti-PD-L1 without ERK 
inhibitor, red are anti-PD-L1 with ERK inhibitor, green are anti-PD-1 without ERK inhibitor, black are 
anti-PD-L1 with ERK inhibitor (B) Percent phagocytosis represents the proportion of Iba1+ cells 
(macrophages) that have circumferentially encircled an Olig2+ neoplastic cell. Counts from at least five 
high powered fields (40x objective) per animal from post-treatment day 10. Each point represents a 
single animal with bilateral tumors from PDGF+Luc glioblastoma (n=5-6 mice per treatment group). 
Orange are IgG control, pink are unilateral radiation only, blue are irradiated side of anti-PD-L1 with 
unilateral radiation, red are abscopal side of  anti-PD-L1 with unilateral radiation (C) Representative 




(macrophages) in PDGF+Luc (radiated side) mouse glioblastoma on post-treatment day 10. Yellow 
arrows indicate phagocytosed Olig2+ neoplastic cells (Magnification, 40x; Scale bar=30µm). P-values 
derived from the non-parametric Mann-Whitney U test, two-sided. Error bars=SEM. P <.01- **, 
P<.0001-****, NS=not significant.  
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